EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in ...

The acquisition creates a clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations.

Beacon Therapeutics presented 3-month interim safety and efficacy data from the Phase 2 DAWN trial of laru-zova (AGTC-501) for X-linked retinitis pigmentosa (XLRP) at the FLORetina ICOOR 2024 meeting ...

DelveInsight has released a report entitled, “Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034.″ This report is a detailed look at diabetic macular edema (DME) ...

Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used ...

It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements ...